Cart
sales@molnova.com
Sapitinib
CAS No. 848942-61-0
Sapitinib ( AZD-8931;AZD8931 )
Catalog No. M16163 CAS No. 848942-61-0
Sapitinib (AZD-8931, AZD8931) is a equipotent, reversible inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4. 3 and 4 nM (phosphorylation inhibition), respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 29 | In Stock |
|
| 5MG | 47 | In Stock |
|
| 10MG | 71 | In Stock |
|
| 25MG | 102 | In Stock |
|
| 50MG | 152 | In Stock |
|
| 100MG | 227 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSapitinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionSapitinib (AZD-8931, AZD8931) is a equipotent, reversible inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4. 3 and 4 nM (phosphorylation inhibition), respectively.
-
DescriptionSapitinib (AZD-8931, AZD8931) is a equipotent, reversible inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4. 3 and 4 nM (phosphorylation inhibition), respectively; displays >1,000-fold selectivity over a panel of 206 of kinases, >100-fold selectivity for MNK1 and Flt3; AZD8931 is significantly more potent than gefitinib or lapatinib in specific squamous cell carcinoma of the head and neck and non-small cell lung carcinoma cell lines; inhibits xenograft growth in a range of models while significantly affecting EGFR, erbB2, and erbB3 phosphorylation and downstream signaling pathways, apoptosis, and proliferation.Colon Cancer Phase 2 Clinical
-
SynonymsAZD-8931;AZD8931
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR;HER2/ErbB2
-
Research AreaCancer
-
IndicationColon Cancer
Chemical Information
-
CAS Number848942-61-0
-
Formula Weight473.93
-
Molecular FormulaC23H25ClFN5O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 33 mg/mL
-
SMILESO=C(NC)CN1CCC(OC2=CC3=C(NC4=CC=CC(Cl)=C4F)N=CN=C3C=C2OC)CC1
-
Chemical Name1-Piperidineacetamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-methyl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hickinson DM, et al. Clin Cancer Res. 2010 Feb 15;16(4):1159-69.
2. Singleton KR, et al. Mol Pharmacol. 2013 Apr;83(4):882-93.
3. Barlaam B, et al. ACS Med Chem Lett. 2013 May 31;4(8):742-6.
4. Mu Z, et al. J Exp Clin Cancer Res. 2014 May 30;33:47.
2. Singleton KR, et al. Mol Pharmacol. 2013 Apr;83(4):882-93.
3. Barlaam B, et al. ACS Med Chem Lett. 2013 May 31;4(8):742-6.
4. Mu Z, et al. J Exp Clin Cancer Res. 2014 May 30;33:47.
molnova catalog
related products
-
EGFR-IN-5
EGFR-IN-5 is a selective inhibitor of EGFR. The IC50s for EGFR, EGFR(L858R), EGFR(L858R/T790M), and EGFR(L858R/T790M/C797S) are 10.4, 1.1, 34, 7.2 nM, respectively.
-
HS-10296
Hs-10296 is an inhibitor of EGFR activation mutation and tolerant mutation of EGFR T790M which has only limited activity against wild-type EGFR.
-
Olmutinib
Olmutinib is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorOlmutinib at 3 μM significantly reversed drug resistance mediated by ABCG2, but not by ABCB1 and ABCC1, by antagonizing the drug efflux function in ABCG2-overexpressing cells.?
